STAT+: AbbVie wins FDA nod for Parkinson’s pill
The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.
AbbVie secures FDA approval for its Parkinson's medication, marking a significant milestone in treating this neurodegenerative disorder. Meanwhile, Zenkuda, a groundbreaking vision-sparing treatment for age-related blindness, demonstrates statistical equivalence to Eylea, a widely-used standard therapy, in a pivotal Phase 3 clinical trial.
Merck has acquired global license rights to a preclinical cancer drug targeting tumors with KRAS G12D mutations, with an initial investment of $400 million from China’s SciBrunch Therapeutics, with a potential value of $2.13 billion if all future milestones are met. Novo Nordisk is increasingly positioning its GLP-1 drugs not just as treatments for chronic diseases, but as consumer products for weight loss, as insurance coverage for these obesity medications remains limited.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
